<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01973517</url>
  </required_header>
  <id_info>
    <org_study_id>27423-001</org_study_id>
    <nct_id>NCT01973517</nct_id>
  </id_info>
  <brief_title>High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases</brief_title>
  <official_title>7T MRI Ferumoxytol-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Feraheme (ferumoxytol) is FDA-approved for iron supplementation and is composed of iron oxide
      nanoparticles classified among the ultra-small superparamagnetic iron oxides (USPIO). In this
      project we hypothesize that Feraheme could become a sensitive and specific marker of active
      inflammation in multiple sclerosis. We will explore this hypothesis taking advantage of ultra
      high field strength (7T) MRI to further increase the effectiveness of the contrast agent
      Feraheme at revealing inflammatory activity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple sclerosis (MS) is a neurological disorder that affects young adults world-wide.
      Feraheme (ferumoxytol) is FDA-approved for iron supplementation and is composed of iron oxide
      nanoparticles classified among the ultra-small superparamagnetic iron oxides (USPIO). After
      IV injection, the particles are taken up by the monocyte-macrophage system and can also be
      used to track macrophage infiltration by magnetic resonance imaging (MRI) after systemic
      injection owing to the strong image contrast of the iron-loaded macrophages. Approximately 24
      hours after their IV injection, free particles are cleared from the circulation and MR signal
      alterations are thought to arise from the capture of particles by circulating phagocytic
      cells that are attracted to inflammatory lesions.

      In this project we hypothesize that Feraheme could become a sensitive and specific marker of
      active inflammation in multiple sclerosis. We will explore this hypothesis by taking
      advantage of ultra high field strength (7T) MRI to further increase the effectiveness of the
      contrast agent Feraheme at revealing inflammatory activity.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Logistical factors affecting recruitment
  </why_stopped>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number and location of enhancing brain lesions seen on 7 tesla MRI following Feraheme administration.</measure>
    <time_frame>Baseline</time_frame>
    <description>Magnetic resonance images of the brains of subjects will be evaluated independently by two expert readers blinded to the demographic and clinical data. The location and number of multiple sclerosis lesions that enhance following Feraheme administration will be recorded. These lesions will be compared with non-enhancing lesions and lesions that enhance with gadolinium-based contrast.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and location of enhancing brain lesions seen on 7 tesla MRI following gadolinium-based contrast administration.</measure>
    <time_frame>Baseline</time_frame>
    <description>Magnetic resonance images of the brains of subjects will be evaluated independently by two expert readers blinded to the demographic and clinical data. The location and number of multiple sclerosis lesions that enhance following gadolinium-based contrast administration will be recorded. These lesions will be compared with non-enhancing lesions and lesions that enhance with Ferahame.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Relapsing Remitting MS</arm_group_label>
    <description>Patients with relapsing remitting multiple sclerosis will be imaged under high-field (7T) MRI prior to and following administration of gadolinium-based contrast (0.1 mmol/kg IV). Afterwards, they will be administered Feraheme 5mg/kg IV via slow push, and they will return 24 hours or later after pharmaceutical administration for post-Feraheme MR imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Feraheme</intervention_name>
    <description>Patients with relapsing remitting multiple sclerosis will be administered Feraheme 5mg/kg IV via slow push once and imaged under high-field MRI at least 24 hours following administration, to allow for adequate clearance of intravascular pharmaceutical.</description>
    <arm_group_label>Relapsing Remitting MS</arm_group_label>
    <other_name>Ferumoxytol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadolinium-based contrast</intervention_name>
    <description>Patients with relapsing remitting multiple sclerosis will be administered gadolinium-based contrast at a dose of 0.1 mmol/kg IV once and imaged under high-field MRI immediately following administration.</description>
    <arm_group_label>Relapsing Remitting MS</arm_group_label>
    <other_name>Gadolinium</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Population will be composed of patients with the diagnosis of relapsing remitting multiple
        sclerosis (MS) who are followed at the Stanford Neurosciences Clinic.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients will be included if they are at least 18 years old and meet the revised
             diagnostic criteria for multiple sclerosis, relapsing remitting type.

          -  Patients will be included based on MR evidence of disease activity after Gadolinium
             (enhanced lesion) on a previous screening MR in the previous 3 weeks days before
             Feraheme administration.

        Exclusion Criteria:

          -  Children (age &lt; 18)

          -  Those who lack decision-making capability

          -  Contraindication to MRI such as pacemaker, other MR-incompatible metal implants or
             claustrophobia

          -  Known allergy to dextran or drugs containing iron salts or any previous history of
             severe allergic reactions

          -  Evidence of iron overload such as hemochromatosis or other hematologic disorders that
             imply iron level superior to the normal level.

          -  Pregnancy or breast feeding.

          -  History of renal disease or estimated glomerular filtration rate (eGFR) using the
             Modification of Diet in Renal Disease (MDRD) &lt;40ml/min/1.73m?
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Zeineh, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian Rutt, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Richard M. Lucas Center for Imaging (of Stanford University)</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Hospitals and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dousset V, Brochet B, Deloire MS, Lagoarde L, Barroso B, Caille JM, Petry KG. MR imaging of relapsing multiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolinium. AJNR Am J Neuroradiol. 2006 May;27(5):1000-5.</citation>
    <PMID>16687532</PMID>
  </reference>
  <reference>
    <citation>Vellinga MM, Oude Engberink RD, Seewann A, Pouwels PJ, Wattjes MP, van der Pol SM, Pering C, Polman CH, de Vries HE, Geurts JJ, Barkhof F. Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement. Brain. 2008 Mar;131(Pt 3):800-7. doi: 10.1093/brain/awn009. Epub 2008 Feb 1.</citation>
    <PMID>18245785</PMID>
  </reference>
  <reference>
    <citation>Tourdias T, Roggerone S, Filippi M, Kanagaki M, Rovaris M, Miller DH, Petry KG, Brochet B, Pruvo JP, Radüe EW, Dousset V. Assessment of disease activity in multiple sclerosis phenotypes with combined gadolinium- and superparamagnetic iron oxide-enhanced MR imaging. Radiology. 2012 Jul;264(1):225-33. doi: 10.1148/radiol.12111416.</citation>
    <PMID>22723563</PMID>
  </reference>
  <reference>
    <citation>Daldrup-Link HE, Rydland J, Helbich TH, Bjørnerud A, Turetschek K, Kvistad KA, Kaindl E, Link TM, Staudacher K, Shames D, Brasch RC, Haraldseth O, Rummeny EJ. Quantification of breast tumor microvascular permeability with feruglose-enhanced MR imaging: initial phase II multicenter trial. Radiology. 2003 Dec;229(3):885-92. Epub 2003 Oct 23.</citation>
    <PMID>14576446</PMID>
  </reference>
  <reference>
    <citation>Metz S, Lohr S, Settles M, Beer A, Woertler K, Rummeny EJ, Daldrup-Link HE. Ferumoxtran-10-enhanced MR imaging of the bone marrow before and after conditioning therapy in patients with non-Hodgkin lymphomas. Eur Radiol. 2006 Mar;16(3):598-607. Epub 2005 Nov 12.</citation>
    <PMID>16284770</PMID>
  </reference>
  <reference>
    <citation>Pai AB, Nielsen JC, Kausz A, Miller P, Owen JS. Plasma pharmacokinetics of two consecutive doses of ferumoxytol in healthy subjects. Clin Pharmacol Ther. 2010 Aug;88(2):237-42. doi: 10.1038/clpt.2010.80. Epub 2010 Jun 30.</citation>
    <PMID>20592725</PMID>
  </reference>
  <reference>
    <citation>Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJ. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol. 2009 Feb;4(2):386-93. doi: 10.2215/CJN.02840608. Epub 2009 Jan 28.</citation>
    <PMID>19176796</PMID>
  </reference>
  <reference>
    <citation>Schwenk MH. Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease. Pharmacotherapy. 2010 Jan;30(1):70-9. doi: 10.1592/phco.30.1.70. Review.</citation>
    <PMID>20030475</PMID>
  </reference>
  <reference>
    <citation>Lu M, Cohen MH, Rieves D, Pazdur R. FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol. 2010 May;85(5):315-9. doi: 10.1002/ajh.21656.</citation>
    <PMID>20201089</PMID>
  </reference>
  <reference>
    <citation>Dousset V, Delalande C, Ballarino L, Quesson B, Seilhan D, Coussemacq M, Thiaudiére E, Brochet B, Canioni P, Caillé JM. In vivo macrophage activity imaging in the central nervous system detected by magnetic resonance. Magn Reson Med. 1999 Feb;41(2):329-33.</citation>
    <PMID>10080281</PMID>
  </reference>
  <reference>
    <citation>Dousset V, Ballarino L, Delalande C, Coussemacq M, Canioni P, Petry KG, Caillé JM. Comparison of ultrasmall particles of iron oxide (USPIO)-enhanced T2-weighted, conventional T2-weighted, and gadolinium-enhanced T1-weighted MR images in rats with experimental autoimmune encephalomyelitis. AJNR Am J Neuroradiol. 1999 Feb;20(2):223-7.</citation>
    <PMID>10094342</PMID>
  </reference>
  <reference>
    <citation>Floris S, Blezer EL, Schreibelt G, Döpp E, van der Pol SM, Schadee-Eestermans IL, Nicolay K, Dijkstra CD, de Vries HE. Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study. Brain. 2004 Mar;127(Pt 3):616-27. Epub 2003 Dec 22.</citation>
    <PMID>14691063</PMID>
  </reference>
  <reference>
    <citation>Ladewig G, Jestaedt L, Misselwitz B, Solymosi L, Toyka K, Bendszus M, Stoll G. Spatial diversity of blood-brain barrier alteration and macrophage invasion in experimental autoimmune encephalomyelitis: a comparative MRI study. Exp Neurol. 2009 Nov;220(1):207-11. doi: 10.1016/j.expneurol.2009.08.027. Epub 2009 Sep 4.</citation>
    <PMID>19733560</PMID>
  </reference>
  <reference>
    <citation>Chin CL, Pai M, Bousquet PF, Schwartz AJ, O'Connor EM, Nelson CM, Hradil VP, Cox BF, McRae BL, Fox GB. Distinct spatiotemporal pattern of CNS lesions revealed by USPIO-enhanced MRI in MOG-induced EAE rats implicates the involvement of spino-olivocerebellar pathways. J Neuroimmunol. 2009 Jun 25;211(1-2):49-55. doi: 10.1016/j.jneuroim.2009.03.012. Epub 2009 Apr 5.</citation>
    <PMID>19346009</PMID>
  </reference>
  <reference>
    <citation>Petry KG, Boiziau C, Dousset V, Brochet B. Magnetic resonance imaging of human brain macrophage infiltration. Neurotherapeutics. 2007 Jul;4(3):434-42. Review.</citation>
    <PMID>17599709</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2013</study_first_submitted>
  <study_first_submitted_qc>October 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2013</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Michael Zeineh</investigator_full_name>
    <investigator_title>Protocol Director</investigator_title>
  </responsible_party>
  <keyword>Multiple sclerosis</keyword>
  <keyword>MRI</keyword>
  <keyword>USPIO</keyword>
  <keyword>Ferumoxytol</keyword>
  <keyword>Feraheme</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Demyelinating Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferrosoferric Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

